To ease long-term drug pricing pressure, extend patent terms by 10 years now

Congress protects song lyrics for nearly a century. Yet life-saving medical inventions, the result of years of scientific risk and billions in investment, expire after just 20 years from filing. That imbalance isn’t just hard to justify. It’s quietly driving up drug prices and weakening incentives for innovation where America needs it most.Patents are the backbone of scientific and engineering progress, but in high-risk regulated sectors such as pharmaceuticals, the current patent term fails to reflect economic reality. Developing a single new drug routinely costs well over $2 billion and often takes more than a decade before it ever reaches patients. By the time regulators approve a treatment, years of patent protection may already be gone. Congress should extend patent terms by 10 years, bringing them to 30, to better align incentives with the realities of modern innovation, and ease long-term pressure on drug prices.The contrast with copyrights is striking. Copyrights for books and songs last for the author’s life plus 70 years, often stretching close to a century. A novelist or songwriter may create a work in days or months, with minimal capital investment, and still enjoy exclusive rights for generations. Inventors, by contrast, face years of uncertainty, regulatory review, and extraordinary cost. Filing and prosecuting a U.S. patent can cost tens of thousands of dollars, and international protection can exceed $100,000 over a patent’s life. In pharmaceuticals, those legal costs are small compared with the billions spent on research, clinical trials, regulatory compliance, and failures, especially when fewer than one in eight drug candidates ever reach the market. The 20-year patent term, adopted in the mid-1990s to harmonize global standards, works best for inventions that can be commercialized quickly. That model breaks down in regulated industries. Clinical development and FDA reviews can consume up to a decade, leaving innovators with little more than a decade of effective market exclusivity. Songwriters and owners of master recordings face no such delays; their work is protected upon creation. It’s hard to justify why a pop song or master recording receives triple the protection of a breakthrough cancer therapy.Extending patent terms would help correct that imbalance. Longer protection would strengthen incentives for research and development, especially in areas with long timelines and high failure rates, such as oncology, neurodegenerative disease, and rare disorders. Critics warn of monopolies, but patents are not open-ended government handouts. They are time-limited rewards granted in exchange for public disclosure, after which competitors, including generic manufacturers, are free to compete. Without robust patent protection, companies would have less reason to invest in risky development, or more reason to protect discoveries as trade secrets where possible.The strongest argument for longer patents, however, lies in the economics behind pricing. Drug development costs have soared, with recent widely cited estimates of more than $2 billion when failures and capital costs are included (Tufts Center for the Study of Drug Development). Under the current system, companies must recover these investments over a shortened effective exclusivity window. The predictable result is pressure toward high launch prices and aggressive rebate negotiations before generic competition arrives.A longer patent term would change the time horizon for those economics. Spreading costs over an additional decade could reduce pressure for front-loaded pricing while still allowing innovators to earn a reasonable return. Instead of pricing a life-saving drug aggressively to recover costs in a single decade, a firm could plan around a longer period of protected revenue, creating more room for stable pricing, negotiated discounts, and patient-access commitments. Patients could gain more predictable access and less front-loaded pricing pressure, while companies would benefit from longer-term revenue stability.History supports this logic. When patents expire, and generic competition enters, prices often fall by 30% to 80%, as occurred with Lipitor™ after patent expiration. That dynamic also helps explain why companies face pressure to recover development costs before generic entry begins. Extending patent terms doesn’t eliminate that competition; it delays it for a defined period, while smoothing the price curve and encouraging moderation rather than front-loaded pricing. Some proposals even tie extensions to price reductions, rewarding companies that lower costs with additional protection. That approach could create a virtuous cycle of innovation, affordability, and access. Skeptics argue that longer patents delay competition. That concern is legitimate, and it reflects the tradeoff patent law has always made. 92% OF AMERICAN CORN IS MODIFIED — AND BIG AG IS SUING TO KEEP THE RECIPE SECRETBut the status quo isn’t delivering affordable drugs or sufficient innovation. Drug prices remain a top concern for Americans, and investment in high-risk fields such as oncology, neurodegenerative diseases, and rare disorders remains difficult to sustain under compressed commercialization timelines. Congress already recognizes regulatory delays through limited patent term adjustments. A measured, uniform 10-year extension would build on that principle, giving innovators a longer horizon to earn returns while creating more room for stable pricing, predictable rebates, and patient-access commitments before generic competition begins.America’s leadership in innovation depends on rewarding creators proportionately to the risks they take. Copyright law grants artists a near-century of protection. Patent law gives scientists barely two decades, much of it lost to regulation. Extending patent terms by 10 years would rebalance incentives, encourage breakthrough research, and help ease long-term drug-pricing pressure by reducing the need to recover development costs over a compressed exclusivity window. Lawmakers should act because the health of American innovation and American patients depends on it.Pete O’Heeron is a biopharma inventor and executive with more than 450 patents issued or pending across biologics, cell therapy, and medical devices. He is the founder and CEO of FibroBiologics and has more than 25 years of experience in drug development, intellectual property strategy, and commercialization.